Incorporated in 2001
Fresh Issue of 165crs (50 for capex | 48 for Working capital | 20 for debt payment) + OFS of 237crs (Partially by promoter & PE Tano selling out as the fund tenure is up)
~ Total raise of 402crs
Windlas Biotech IPO notes 💊
'What's in a name? that which we call a rose by any other name would smell as sweet' ~Shakespeare
Hit the 'retweet' & help us educate more investors
A thread 🧵👇
#IPOwithJST
Incorporated in 2001
Fresh Issue of 165crs (50 for capex | 48 for Working capital | 20 for debt payment) + OFS of 237crs (Partially by promoter & PE Tano selling out as the fund tenure is up)
~ Total raise of 402crs
A Contract manufacturer for formulation cos. (204 in total) for Indian markets & a small domestic OTC biz
3279 products, 4 plants with 700cr tablets/capsules capacity
Emphasis on chronic (60% of rev) & complex generics (70% of rev)
Revenues:
FY11 - 100cr 👉 FY14 - 200cr 👉 FY21 - 400cr
Growth is similar to the Indian pharmaceutical sector, not gaining any market share even after increasing products.
Customers include Pfizer, Sanofi India, Eris, Cadila, etc.
400+ organized & 15000 unorganized players in the same space: 2% market share
Some of the things that can drive consolidation: Customers preferring better compliance
However, a single customer usually has 35-40 contract manufacturers for products.
Scale: Players much larger also show a lack of any improvement in metrics.
Remains a low margin & high asset turnover business.
Top customer accounts for 11% of rev & Top 10 account for 58%
Interestingly, ramped up number of customers from 97 to 204 in the last 2yrs, however, the concentration remains constant.
3-4crs spends: at 1% of sales, Increased complex portfolio to 934
Complex generic products have technical complexity in (i) manufacturing or handling of the API; or (ii) formulation; or (iii) route of delivery; or (iv) pairing with a device to make a drug-device combo.
Utilization at 35-40% currently, can go up to 60-65% before they would have to increase capacity again.
- Will look for inorganic growth
- Industry to grow at 1.25-1.5x GDP: Increased capacities inline
- To invest 50crs in Injectables facility
- Increase customer base
- Scale-up Domestic OTC & trade generics business
- Bad Cashflow conversion (20-30% EBITDA) due to huge WC investments
- Low margin business (4-5% net & 10-12% EBITDA & 35% gross margins)
- WC days to stay at 65-75 days
- Asset turnover at 4-5x & can take it to 6-7x
- Rev scaleup needs to be monitored
- Dependence on their customers doing well: 90% in B2B business
- Highly competitive, no moat & gruesome business
- Shady dealings with a promoter owned subsidiary: Windlas Healthcare
- No geographical diversification wrt plants.
- Formulations players backwardly integrating their operations: Eris doing the same as it helps them maintain consistent quality & achieve higher margins
- API prices going up (No long term contract with supplier)
- Litigations 👇
- Loss-making Subsidiaries.
At valuations of 2.3x P/S, 19x P/EBITDA & 65x PE, this is valued much higher than most Indian branded formulations are; leaving little to nothing on the table for the investors.
End of Thread.
